Wells Fargo & Company Forecasts Strong Price Appreciation for Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics (NASDAQ:NTLA) had its target price hoisted by investment analysts at Wells Fargo & Company from $12.00 to $15.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 8.54% from the company’s current price.

A number of other equities research analysts have also weighed in on NTLA. Wedbush dropped their price target on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Oppenheimer set a $27.00 target price on shares of Intellia Therapeutics in a research report on Friday, November 7th. Chardan Capital reaffirmed a “buy” rating and issued a $26.00 price target on shares of Intellia Therapeutics in a report on Friday, February 27th. KeyCorp set a $25.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, January 28th. Finally, Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $19.59.

Intellia Therapeutics Trading Up 1.6%

Shares of NTLA opened at $13.82 on Tuesday. The firm has a market cap of $1.63 billion, a PE ratio of -3.61 and a beta of 2.10. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The stock has a fifty day moving average price of $12.17 and a 200-day moving average price of $13.10.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same period in the previous year, the business earned ($1.27) EPS. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. As a group, research analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In related news, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the transaction, the executive vice president owned 101,528 shares of the company’s stock, valued at $935,072.88. This trade represents a 9.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,051 shares of company stock worth $488,600 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NTLA. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics during the third quarter worth about $30,000. Blue Bell Private Wealth Management LLC acquired a new position in Intellia Therapeutics in the third quarter valued at approximately $30,000. Advisory Services Network LLC purchased a new stake in Intellia Therapeutics in the 3rd quarter worth approximately $33,000. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth approximately $26,000. Finally, Comerica Bank increased its holdings in shares of Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.